GO:0005601 classical-complement-pathway C3/C5 convertase complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005601 describes the classical-complement-pathway C3/C5 convertase complex, a heterodimeric enzyme composed of one C4b and one C2a subunit that cleaves complement components C3 and C5.
• The C2a subunit is the catalytic serine protease, but it cannot cleave substrates alone; C4b provides the binding platform and stabilizes the complex.
• Formation of the classical pathway C3 convertase requires prior activation of C1, cleavage of C4 and C2, and assembly of C4b2a on target surfaces.
• The classical pathway C3/C5 convertase is a key driver of complement-mediated tissue injury in diseases such as membranous nephropathy and IgA nephropathy.
• High-affinity C5 convertase activity of the classical pathway requires additional C3b molecules bound to C4b2a, forming a C4b2aC3b complex.
• Research on this complex uses knockout, point-mutation, knock-in, and overexpression cell models, combined with CRISPR screening and bioinformatics to dissect gene function.
Description
The classical-complement-pathway C3/C5 convertase complex (GO:0005601) is a central enzymatic assembly of the complement system, a major arm of innate immunity. This heterodimeric complex, composed of one C4b and one C2a subunit, catalyzes the cleavage of complement components C3 and C5, thereby amplifying the complement cascade and driving downstream effector functions such as opsonization, inflammation, and membrane attack complex formation. The complex is a cellular component ontology term that defines a specific molecular machine rather than a single gene product, reflecting its role as a multi-subunit enzyme. Understanding its structure, assembly, and regulation is critical for researchers studying complement-mediated diseases, including renal pathologies, autoimmune disorders, and inflammatory conditions. The classical pathway C3/C5 convertase is a validated target for therapeutic intervention, and recent structural and functional studies have provided unprecedented insights into its catalytic mechanism and substrate recognition. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0005601, its constituent genes, disease relevance, and experimental strategies for investigation.
classical-complement-pathway C3/C5 convertase complex At A Glance
| GO ID | GO:0005601 |
|---|---|
| GO term | classical-complement-pathway C3/C5 convertase complex |
| Ontology | cellular_component |
| Synonym | None |
| Major function | Catalyzes cleavage of complement components C3 and C5 in the classical pathway of complement activation |
| Subunit composition | Heterodimer of C4b and C2a; C2a is the catalytic serine protease, C4b is the non-catalytic platform |
| Assembly requirement | Requires prior activation of C1, cleavage of C4 and C2, and deposition of C4b on target surfaces |
| C5 convertase form | High-affinity C5 convertase requires additional C3b molecules bound to C4b2a, forming C4b2aC3b |
| Disease relevance | Implicated in membranous nephropathy, IgA nephropathy, and other complement-mediated diseases |
What Is GO:0005601?
GO:0005601 defines the classical-complement-pathway C3/C5 convertase complex as a heterodimeric protein complex that catalyzes the cleavage of complement components C3 and C5, acting in the classical pathway of complement activation. The complex consists of one monomer of C2a and one monomer of C4b. C2a is the catalytic subunit, but it cannot catalyze cleavage alone; C4b provides the necessary binding interface and cofactor functions. This complex is a cellular component, meaning it is a stable assembly of proteins located on target surfaces, typically microbial membranes or host cell surfaces where complement activation occurs.
Why Is classical-complement-pathway C3/C5 convertase complex Important in Cell Biology?
The classical-complement-pathway C3/C5 convertase complex is a pivotal enzymatic node in the complement cascade, and its dysregulation is directly linked to human disease. In membranous nephropathy, classical pathway activation triggers pathogenic complement deposition and tissue injury. In IgA nephropathy, in situ assessment of glomerular C3/C5 convertases indicates ongoing complement activation, correlating with disease activity. The complex is also a target for therapeutic development, as inhibiting its formation or activity can mitigate complement-mediated damage. Understanding its molecular architecture and regulation is therefore essential for researchers in immunology, nephrology, and drug discovery.
• Central amplifier of the classical complement pathway, generating C3b for opsonization and C5b for membrane attack complex assembly.
• Directly implicated in the pathogenesis of membranous nephropathy through classical pathway activation.
• Associated with ongoing complement activation in IgA nephropathy, as shown by in situ assessment of glomerular C3/C5 convertases.
• Requires a unique heterodimeric assembly of C4b and C2a, making it a specific target for inhibitor design.
• High-affinity C5 convertase activity depends on additional C3b molecules, revealing a regulatory mechanism for C5 cleavage.
• Subject to regulation by complement inhibitors such as factor H and factor I, which decay the complex or cleave C4b.
• Provides a model system for studying serine protease catalysis within a multi-protein complex.
• Its formation is triggered by immune complexes and antibody-antigen interactions, linking adaptive and innate immunity.
• Genetic or acquired deficiencies in complement components alter convertase activity and disease susceptibility.
• Emerging evidence suggests complement activation pathways beyond the classical pathway may converge on this complex.
What Happens During classical-complement-pathway C3/C5 convertase complex?
Initiation of the Classical Pathway
In simple terms: The classical pathway starts when antibodies or other activators bind to a target, triggering a domino effect of complement proteins.
The classical pathway is initiated by the binding of C1q to immune complexes or pathogen surfaces, leading to activation of C1r and C1s serine proteases. Activated C1s cleaves C4 into C4a and C4b, exposing a reactive thioester in C4b that covalently attaches to nearby surfaces. C1s also cleaves C2 into C2a and C2b, and C2a binds to surface-deposited C4b to form the C4b2a complex, which is the classical pathway C3 convertase. This assembly is magnesium-dependent and occurs on the target membrane.
C3 Convertase Activity and Amplification
In simple terms: The C4b2a complex acts like a molecular scissors that cuts C3 into active fragments, amplifying the complement response.
The C4b2a complex catalyzes the cleavage of C3 into C3a and C3b. C3a is an anaphylatoxin that promotes inflammation, while C3b covalently binds to surfaces and forms new C3 convertases, creating a positive feedback loop. Structural studies have revealed that C4b provides the binding platform for C3, while C2a contains the catalytic serine protease domain that executes cleavage. The complex is inherently unstable and undergoes spontaneous decay unless stabilized by properdin or other factors.
Formation of the C5 Convertase
In simple terms: When enough C3b accumulates, the C3 convertase changes its preference and starts cutting C5, leading to the membrane attack complex.
The classical pathway C5 convertase is formed when additional C3b molecules bind to the C4b2a complex, creating a C4b2aC3b trimolecular assembly. This high-affinity C5 convertase exhibits specificity for C5, cleaving it into C5a and C5b. C5a is a potent anaphylatoxin and chemotactic factor, while C5b initiates assembly of the membrane attack complex (C5b-9) that lyses target cells. The transition from C3 to C5 convertase activity is a critical regulatory step in complement activation.
Structural Insights into the Convertase Complex
In simple terms: Recent high-resolution structures show exactly how the C4b and C2a subunits fit together and recognize their substrates.
Cryo-electron microscopy and crystallography studies have provided detailed structural insights into the classical pathway C3 convertase. The C4b subunit presents a large binding surface for C3, while the C2a serine protease domain adopts a conformation that positions the catalytic triad for efficient cleavage. These structures have revealed that C2a undergoes significant conformational changes upon binding to C4b, which is required for its catalytic activity. The structural data also explain how the complex discriminates between C3 and C5, and how additional C3b molecules convert it into a C5 convertase.
Regulation and Decay of the Convertase
In simple terms: The convertase is tightly controlled by inhibitor proteins that either break it apart or chew up its subunits.
The classical pathway C3/C5 convertase is regulated by complement inhibitors such as factor H, factor I, and C4b-binding protein (C4BP). Factor I cleaves C4b in the presence of cofactors, preventing reassembly of the complex. Decay-accelerating factor (DAF/CD55) and complement receptor 1 (CR1) accelerate the spontaneous decay of C4b2a. Properdin stabilizes the convertase and extends its half-life, enhancing complement activation. Dysregulation of these control mechanisms contributes to complement-mediated diseases.
Key Genes Involved in GO:0005601 classical-complement-pathway C3/C5 convertase complex
The classical-complement-pathway C3/C5 convertase complex is composed of and regulated by a set of complement proteins encoded by specific genes; the table below lists the major genes and their roles.
| Gene | Major Role | Research Relevance |
|---|---|---|
| C4A | Encodes complement C4, which is cleaved to C4b; C4b is a structural subunit of the convertase | Genetic variants influence complement activity and disease susceptibility |
| C4B | Encodes complement C4; C4b forms the binding platform for C2a | Isoform differences affect convertase assembly and function |
| C2 | Encodes complement C2, which is cleaved to C2a; C2a is the catalytic serine protease subunit | Polymorphisms linked to complement-mediated diseases |
| C3 | Encodes complement C3, the substrate of the C3 convertase and a component of the C5 convertase | Central to amplification and effector functions |
| C5 | Encodes complement C5, the substrate of the C5 convertase | Target for therapeutic antibodies in complement diseases |
| C1QA | Encodes C1q A chain, part of the C1 complex that initiates the classical pathway | Deficiency causes immune complex disease |
| C1QB | Encodes C1q B chain, required for C1 activation | Autoantibodies to C1q are pathogenic |
| C1QC | Encodes C1q C chain, essential for C1 complex assembly | Mutations associated with lupus-like syndromes |
| C1R | Encodes C1r serine protease, activates C1s | Deficiency leads to complement dysfunction |
| C1S | Encodes C1s serine protease, cleaves C4 and C2 | Target for inhibitor development |
| CFH | Encodes factor H, a regulator that accelerates decay of C3 convertase | Mutations linked to atypical hemolytic uremic syndrome |
| CFI | Encodes factor I, which cleaves C4b and C3b in the presence of cofactors | Deficiency causes uncontrolled complement activation |
| C4BPA | Encodes C4b-binding protein alpha chain, a cofactor for factor I | Regulates classical pathway convertase |
| C4BPB | Encodes C4b-binding protein beta chain, part of C4BP | Modulates complement inhibition |
| CD55 | Encodes decay-accelerating factor (DAF), which destabilizes C4b2a | Protects host cells from complement lysis |
| CD35 | Encodes complement receptor 1 (CR1), which accelerates convertase decay | Important for immune complex clearance |
| CFP | Encodes properdin, which stabilizes the C3 convertase | Enhances complement activation |
| C5AR1 | Encodes C5a receptor 1, mediates inflammatory effects of C5a | Therapeutic target in inflammatory diseases |
How Is classical-complement-pathway C3/C5 convertase complex Regulated?
The classical-complement-pathway C3/C5 convertase complex is regulated at multiple levels to prevent uncontrolled complement activation on host tissues. Factor I, a serine protease, cleaves C4b in the presence of cofactors such as C4b-binding protein (C4BP) and complement receptor 1 (CR1), thereby irreversibly inactivating the convertase. Decay-accelerating factor (DAF/CD55) and CR1 accelerate the spontaneous dissociation of C2a from C4b, shortening the half-life of the complex. Properdin stabilizes the convertase and competes with factor H, enhancing complement activation. Additionally, factor H acts as a cofactor for factor I-mediated cleavage of C3b and accelerates decay of the alternative pathway C3 convertase, indirectly influencing classical pathway activity. Dysregulation of these regulators, often through genetic mutations or autoantibodies, leads to excessive convertase activity and tissue damage in diseases such as membranous nephropathy and IgA nephropathy.
classical-complement-pathway C3/C5 convertase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| C3 | Membranous nephropathy; complement-mediated glomerular injury | C3 knockout podocyte cell line; CRISPR knock-in of patient variants |
| C5 | IgA nephropathy; C5 convertase activity | C5 point-mutation cell model to block cleavage; overexpression of C5 in mesangial cells |
| C4A | Autoimmune diseases; classical pathway activation | C4A knockout macrophage; knock-in of C4A vs C4B isoforms |
| CFH | Atypical hemolytic uremic syndrome; regulator dysfunction | CFH knockout endothelial cells; point-mutation knock-in of risk variants |
| CFI | Complement dysregulation; recurrent infections | CFI knockout hepatocyte; overexpression of mutant CFI |
Membranous Nephropathy
Membranous nephropathy is a leading cause of nephrotic syndrome in adults, characterized by immune complex deposition in the glomerular basement membrane. The classical pathway triggers pathogenic complement activation in membranous nephropathy, with C4b2a convertase playing a central role in generating C3b and C5b-9. In situ assessment of glomerular C3/C5 convertases indicates ongoing complement activation, correlating with disease activity and proteinuria. Therapeutic strategies targeting the classical pathway convertase are under investigation.
IgA Nephropathy
IgA nephropathy is the most common primary glomerulonephritis worldwide, and complement activation is a key pathogenic mechanism. In situ assessment of glomerular C3/C5 convertases in IgA nephropathy biopsies indicates ongoing complement activation, suggesting that the classical pathway convertase contributes to renal injury. The presence of C4d, a cleavage product of C4, in glomeruli supports classical pathway involvement. Targeting the convertase complex may offer therapeutic benefit.
Autoimmune and Inflammatory Diseases
Dysregulation of the classical pathway C3/C5 convertase is implicated in systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune conditions where immune complexes activate complement. Deficiencies in complement regulators such as factor H and factor I lead to uncontrolled convertase activity and tissue damage. Granzyme K has been identified as driving a newly identified pathway of complement activation, potentially converging on the convertase complex. Understanding these mechanisms is critical for developing targeted therapies.
From classical-complement-pathway C3/C5 convertase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of C3 convertase subunit C2a abolish classical pathway activation? | C2 knockout cell line (e.g., HepG2) generated by CRISPR |
| Can a point mutation in the catalytic triad of C2a eliminate convertase activity? | C2 point-mutation knock-in cell model (e.g., H293T) expressing mutant C2a |
| Does tagging C4b with a fluorescent protein affect convertase assembly? | C4b knock-in with GFP tag in a complement-producing cell line |
| Does overexpression of C4b-binding protein inhibit convertase formation? | C4BP overexpression in endothelial cells |
| Can CRISPR library screening identify novel regulators of the classical pathway convertase? | Genome-wide CRISPR knockout library in a complement activation reporter cell line |
| Does a disease-associated C3 variant alter C5 convertase specificity? | C3 knock-in cell model expressing the variant; functional hemolysis assay |
How to Study the classical-complement-pathway C3/C5 convertase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-electron microscopy | 3D structure of the convertase complex at near-atomic resolution | Understanding subunit interactions and catalytic mechanism |
| Hemolytic assay | Functional activity of the classical pathway convertase | Screening for complement inhibitors or genetic variants |
| ELISA for C3a/C5a | Generation of anaphylatoxins as a readout of convertase activity | Quantifying complement activation in plasma or cell culture |
| CRISPR knockout screening | Identification of genes required for convertase function | Discovery of novel regulators of the classical pathway |
| Immunofluorescence | In situ detection of C4d/C3b in tissue biopsies | Diagnosis and monitoring of complement-mediated diseases |
| Surface plasmon resonance | Binding affinity between C4b and C2a or C3 | Characterizing molecular interactions and inhibitor efficacy |
| RNA-seq | Expression levels of complement genes | Identifying co-regulated gene networks in disease models |
| Proteomics | Protein composition of the convertase complex | Validating subunit stoichiometry and post-translational modifications |
Structural Biology (Cryo-EM and Crystallography)
High-resolution structural studies have provided detailed insights into the classical pathway C3 convertase complex, revealing the architecture of the C4b2a heterodimer and its interaction with C3. Cryo-electron microscopy has been used to determine the structure of the complex in different conformational states, elucidating the catalytic mechanism of C2a. These methods are essential for understanding how the convertase recognizes substrates and how mutations affect function.
Functional Complement Assays
Hemolytic assays measure the ability of the classical pathway convertase to lyse antibody-sensitized sheep erythrocytes, providing a functional readout of convertase activity. ELISA-based assays can quantify C3a, C5a, and C5b-9 generation in plasma or cell culture supernatants. These assays are used to assess the impact of genetic variants or inhibitors on convertase function.
CRISPR Screening and Bioinformatics
Genome-wide CRISPR knockout screens in complement-producing cell lines can identify novel genes that regulate the classical pathway convertase. Bioinformatics analysis of transcriptomic and proteomic data can reveal co-expression networks and pathways associated with convertase components. These approaches accelerate target discovery and validation.
In Situ Assessment in Tissue Biopsies
Immunofluorescence or immunohistochemistry can detect C3/C5 convertase components (e.g., C4d, C3b) in tissue biopsies from patients with complement-mediated diseases. In situ assessment of glomerular C3/C5 convertases in IgA nephropathy indicates ongoing complement activation and correlates with disease severity. This method provides spatial information about convertase activity in disease pathology.
How CRISPR Can Be Used to Study GO:0005601 classical-complement-pathway C3/C5 convertase complex
Knockout
CRISPR knockout of genes encoding convertase subunits (e.g., C2, C4) or regulators (e.g., CFH, CFI) in cell lines such as HepG2 or HEK293T can abolish or dysregulate classical pathway activity. These models are used to dissect the contribution of individual genes to convertase assembly and function. Knockout of C2, for example, prevents formation of the C4b2a complex and blocks C3 cleavage.
Point Mutation
Point mutations in the catalytic triad of C2a (e.g., His, Asp, Ser residues) can be introduced by CRISPR to generate catalytically inactive convertase complexes. Such models help distinguish between the structural and catalytic roles of C2a. Disease-associated point mutations in C3 or C4 can also be knocked in to study their impact on convertase activity and substrate specificity.
Knock-in
Knock-in of tagged versions of C4b or C2a (e.g., GFP, FLAG) allows real-time visualization and purification of the convertase complex from cell lysates. Knock-in of patient-derived mutations in C3 or CFH can create isogenic cell models to study disease mechanisms. These models are valuable for testing targeted therapies.
Overexpression
Overexpression of complement regulators such as C4BP or factor H in endothelial cells can suppress convertase activity and protect against complement-mediated lysis. Conversely, overexpression of C3 or C5 can enhance convertase substrate availability and amplify complement activation. These models are used to study the balance between activation and regulation.
How EDITGENE Supports classical-complement-pathway C3/C5 convertase complex Research
Researchers studying classical-complement-pathway C3/C5 convertase complex-related genes often need to determine whether a candidate gene is causally involved in complement activation, disease pathogenesis, or therapeutic response. Generating precise genetic models is essential to move from correlation to causation. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for classical-complement-pathway C3/C5 convertase complex research.
Frequently Asked Questions About classical-complement-pathway C3/C5 convertase complex
What is the classical-complement-pathway C3/C5 convertase complex?
It is a heterodimeric protein complex (GO:0005601) composed of C4b and C2a that cleaves complement components C3 and C5 in the classical pathway of complement activation.
What genes are involved in the classical-complement-pathway C3/C5 convertase complex?
The complex is composed of C4b (from C4A or C4B) and C2a (from C2), and its activity is regulated by genes such as CFH, CFI, C4BPA, CD55, and CD35.
What is the function of the classical pathway C3 convertase?
It catalyzes the cleavage of C3 into C3a and C3b, amplifying the complement cascade and promoting opsonization and inflammation.
How is the classical pathway C5 convertase formed?
It forms when additional C3b molecules bind to the C4b2a complex, creating a C4b2aC3b assembly with high affinity for C5.
What diseases are associated with the classical-complement-pathway C3/C5 convertase complex?
It is implicated in membranous nephropathy, IgA nephropathy, and other complement-mediated diseases such as autoimmune disorders.
What is the role of C2a in the classical pathway convertase?
C2a is the catalytic serine protease subunit that cleaves C3 and C5, but it requires C4b for stability and substrate binding.
How is the classical pathway C3/C5 convertase regulated?
It is regulated by factor I, factor H, C4b-binding protein, decay-accelerating factor (CD55), and complement receptor 1 (CD35), which promote decay or cleavage of C4b.
What experimental models are used to study the classical-complement-pathway C3/C5 convertase complex?
CRISPR knockout, point-mutation, knock-in, and overexpression cell models, along with structural biology, functional complement assays, and CRISPR screening, are commonly used.
Can CRISPR be used to study the classical-complement-pathway C3/C5 convertase complex?
Yes, CRISPR knockout of C2 or C4 abolishes convertase formation, while point mutations in C2a catalytic residues eliminate activity, enabling precise functional dissection.
What is the structural basis of classical pathway C3 convertase activity?
Recent cryo-EM structures show that C4b provides a binding platform for C3, while C2a undergoes conformational changes to position its catalytic triad for cleavage.
Conclusion
The classical-complement-pathway C3/C5 convertase complex (GO:0005601) is a central enzymatic assembly in the complement cascade, with critical roles in innate immunity and disease pathogenesis. Its heterodimeric structure, comprising C4b and C2a, enables the cleavage of C3 and C5, driving inflammation, opsonization, and membrane attack complex formation. Dysregulation of this complex is linked to membranous nephropathy, IgA nephropathy, and other complement-mediated diseases, making it a prime therapeutic target. Advances in structural biology, CRISPR-based genetic models, and functional assays continue to unravel its molecular mechanisms and regulation. Researchers can leverage EDITGENE's comprehensive CRISPR services to generate precise cell models and accelerate discoveries in complement biology.
References
- 1. Seifert L et al.. 2023. The classical pathway triggers pathogenic complement activation in membranous nephropathy.. Nat Commun 14(1):473 PMID: 36709213
- 2. Ling M et al.. 2019. Analysis of the Complement System in the Clinical Immunology Laboratory.. Clin Lab Med 39(4):579-590 PMID: 31668271
- 3. De la O Becerra KI et al.. 2025. Structural insights into C3 convertase activity of the classical pathway of complement.. Nat Commun 17(1):993 PMID: 41413058
- 4. Kavanagh D et al.. 2025. Factor B as a therapeutic target for the treatment of complement-mediated diseases.. Front Immunol 16:1537974 PMID: 40028332
- 5. Jia C et al.. 2026. Complement C3 recognition by C3 convertases.. Sci Adv 12(8):eadz5404 PMID: 41719406
- 6. Donado CA et al.. 2024. Granzyme K drives a newly-intentified pathway of complement activation.. bioRxiv PMID: 38826230
- 7. Obrecht A et al.. 2026. In situ assessment of glomerular C3/C5 convertases indicates ongoing complement activation in IgA nephropathy.. Nephrol Dial Transplant 41(4):715-724 PMID: 41032319
- 8. Rawal N et al.. 2003. Formation of high affinity C5 convertase of the classical pathway of complement.. J Biol Chem 278(40):38476-83 PMID: 12878586
